Molecular Templates, Inc. (MTEM)
- Previous Close
1.4100 - Open
1.3200 - Bid 1.4300 x 100
- Ask 1.5800 x 100
- Day's Range
1.3100 - 1.5050 - 52 Week Range
1.2700 - 9.4500 - Volume
65,132 - Avg. Volume
75,001 - Market Cap (intraday)
9.81M - Beta (5Y Monthly) 1.15
- PE Ratio (TTM)
-- - EPS (TTM)
-1.8000 - Earnings Date May 14, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.50
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
www.mtem.comRecent News: MTEM
Performance Overview: MTEM
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MTEM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MTEM
Valuation Measures
Market Cap
9.22M
Enterprise Value
9.92M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.12
Price/Book (mrq)
2.19
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-14.18%
Return on Assets (ttm)
-9.84%
Return on Equity (ttm)
--
Revenue (ttm)
57.31M
Net Income Avi to Common (ttm)
-8.12M
Diluted EPS (ttm)
-1.8000
Balance Sheet and Cash Flow
Total Cash (mrq)
11.52M
Total Debt/Equity (mrq)
290.36%
Levered Free Cash Flow (ttm)
-32.62M
Research Analysis: MTEM
Company Insights: MTEM
MTEM does not have Company Insights